![]() |
![]() |
Legal status
Patent revoked (after opposition at EPO)
(51) | INT.CL. | C07D 401/12 | (2006.01) |
A61K 31/506 | (2006.01) | ||
A61P 35/00 | (2006.01) |
(11) | Number of the document | 2651918 |
(13) | Kind of document | T |
(96) | European patent application number | 11806079.7 |
Date of filing the European patent application | 2011-12-15 | |
(97) | Date of publication of the European application | 2013-10-23 |
(45) | Date of publication and mention of the grant of the patent | 2017-07-12 |
(46) | Date of publication of the claims translation | 2017-10-10 |
(86) | Number | PCT/US2011/065030 |
Date | 2011-12-15 |
(87) | Number | WO 2012/082972 |
Date | 2012-06-21 |
(30) | Number | Date | Country code |
201061424194 P | 2010-12-17 | US |
(72) |
FENG, Lili, US
GONG, Baoqing, US
KARPINSKI, Piotr H., US
WAYKOLE, Liladhar Murlidhar, US
|
(73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
(74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
(54) | 5-Chlor-N2-(2-izopropoksi-5-metil-4-piperidin-4-il-fenil)-N4[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamino kristalinės formos |
CRYSTALLINE FORMS OF 5-CHLORO-N2-(2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL)-N4[2-(PROPANE-2-SULFONYL)-PHENYL]-PYRIMIDINE-2,4-DIAMINE |
Payment date | Validity (years) | Amount | |
2021-11-29 | 11 | 289.00 EUR |
Patent revoked (after opposition at EPO) | ||
Invalidation date | 2022-06-01 |